In the latest trading session, GlaxoSmithKline (GSK) closed at $41.27. This move was narrower than the S&P 500’s daily loss of 3.25%.
Coming into today, shares of the drug developer had lost 3.85% in the past month. In that same time, the Medical sector lost 1.96%, while the S&P 500 lost 5.62%.
GlaxoSmithKline will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.68, down 13.92% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $11.12 billion, down 1.72% from the year-ago period. Yahoo analysts are expecting earnings of $3.18 per share and revenue of $48.8 billion. These totals would mark changes of +2.25% and +4.08%, respectively, from last year. It is also worth noting that GSK currently has a PEG ratio of 1.87. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company’s expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.12 based on yesterday’s closing prices.
Source - database | Page ID - 829 -